Why Cidara Therapeutics Stock Absolutely Soared Today

Cidara Therapeutics just delivered the kind of explosive performance that makes traditional finance veterans clutch their pearls.

Clinical Trial Triumph

The biopharma player smashed expectations with breakthrough results that sent institutional money scrambling for position.

Market Momentum Ignites

Trading volume surged as retail investors piled in, creating that beautiful FOMO cascade Wall Street analysts pretend to understand but never see coming.

Another reminder that while traditional markets play checkers, breakthrough medical innovations are playing 4D chess—and today, Cidara just checkmated the entire board.

Reporting a breakthrough

Cidara announced before market open that the U.S. Food and Drug Administration (FDA) has granted the healthcare company's investigational flu drug its Breakthrough Therapy designation. With that tag, the FDA is set to accelerate the approval decision process for the medication.

Image source: Getty Images.

The drug, designated CD388 by Cidara, is a non-vaccine treatment aimed at preventing seasonal flu. It targets people who want or need to have some protection from the highly common affliction, but are medically unable (or simply unwilling) to be administered a traditional vaccine.

Previously, CD388 was granted the U.S. regulator's fast-track designation for review. This, combined with the Breakthrough Therapy tag, means a decision is more likely to be handed down in the very NEAR future.

Far advanced in the pipeline

In its press release trumpeting the news, Cidara quoted CEO Jeffrey Stein as saying that the FDA's MOVE "underscores the importance of CD388 as a potential new non-vaccine prophylactic for seasonal influenza."

The drug is currently in phase 3 clinical testing, the company added.